Advertisement

Digestive Diseases and Sciences

, Volume 62, Issue 5, pp 1119–1130 | Cite as

Potential for Screening for Pancreatic Exocrine Insufficiency Using the Fecal Elastase-1 Test

  • J. Enrique Domínguez-Muñoz
  • Philip D. Hardt
  • Markus M. Lerch
  • Matthias J. Löhr
Review

Abstract

The early diagnosis of pancreatic exocrine insufficiency (PEI) is hindered because many of the functional diagnostic techniques used are expensive and require specialized facilities, which prevent their widespread availability. We have reviewed current evidence in order to compare the utility of these functional diagnostic techniques with the fecal elastase-1 (FE-1) test in the following three scenarios: screening for PEI in patients presenting with symptoms suggestive of pancreatic disease, such as abdominal pain or diarrhea; determining the presence of PEI in patients with an established diagnosis of pancreatic disease, such as chronic pancreatitis or cystic fibrosis; determining exocrine status in disorders not commonly tested for PEI, but which have a known association with this disorder. Evidence suggests the FE-1 test is reliable for the evaluation of pancreatic function in many pancreatic and non-pancreatic disorders. It is non-invasive, is less time-consuming, and is unaffected by pancreatic enzyme replacement therapy. Although it cannot be considered the gold-standard method for the functional diagnosis of PEI, the advantages of the FE-1 test make it a very appropriate test for screening patients who may be at risk of this disorder.

Keywords

Fecal elastase-1 Pancreatic exocrine insufficiency Chronic pancreatitis Diabetes mellitus Malnutrition 

Notes

Acknowledgments

Editorial assistance was provided to authors during the drafting of this manuscript by Martin Wallace PhD (Alpharmaxim Healthcare Communications). Funding for this assistance was provided by Mylan.

Compliance with ethical standards

Conflicts of interest

Prof. Domínguez-Muñoz has participated in consulting and speaking activities for Abbott Laboratories Ltd., Mylan N.V., and Allergan plc. Prof. Hardt has participated in consulting and speaking activities for Abbott Laboratories Ltd., AbbVie Ltd., and Shire plc. Prof. Lerch has participated in consulting and speaking activities for AbbVie Ltd., Abbott Laboratories Ltd., Dr. Falk Pharma GmbH, AstraZeneca plc., Nordmark Arzneimittel GmbH & Co. KG, Centogene AG, and KMG. Prof. Löhr has participated in consulting and speaking activities for Abbott Laboratories Ltd., and consultancy activities for Nordmark Arzneimittel GmbH & Co. KG.

References

  1. 1.
    Leeds JS, Oppong K, Sanders DS. The role of fecal elastase-1 in detecting exocrine pancreatic disease. Nat Rev Gastroenterol Hepatol. 2011;8:405–415.CrossRefPubMedGoogle Scholar
  2. 2.
    Sahai AV, Mishra G, Penman ID, et al. EUS to detect evidence of pancreatic disease in patients with persistent or nonspecific dyspepsia. Gastrointest Endosc. 2000;52:153–159.CrossRefPubMedGoogle Scholar
  3. 3.
    Laterza L, Scaldaferri F, Bruno G, et al. Pancreatic function assessment. Eur Rev Med Pharmacol Sci. 2013;17:65–71.PubMedGoogle Scholar
  4. 4.
    Martin TC, Scourfield A, Rockwood N, et al. Pancreatic insufficiency in patients with HIV infection: role of didanosine questioned. HIV Med. 2013;14:161–166.CrossRefPubMedGoogle Scholar
  5. 5.
    Leeds JS, Hopper AD, Hurlstone DP, et al. Is exocrine pancreatic insufficiency in adult coeliac disease a cause of persisting symptoms? Aliment Pharmacol Ther. 2007;25:265–271.CrossRefPubMedGoogle Scholar
  6. 6.
    Domínguez-Muñoz JE. Pancreatic enzyme replacement therapy: exocrine pancreatic insufficiency after gastrointestinal surgery. HPB (Oxford). 2009;11:3–6.CrossRefGoogle Scholar
  7. 7.
    Nakajima K, Oshida H, Muneyuki T, Kakei M. Pancrelipase: an evidence-based review of its use for treating pancreatic exocrine insufficiency. Core Evid. 2012;7:77–91.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Lindkvist B. Diagnosis and treatment of pancreatic exocrine insufficiency. World J Gastroenterol. 2013;19:7258–7266.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    DiMagno EP, Go VL, Summerskill WH. Relations between pancreatic enzyme ouputs and malabsorption in severe pancreatic insufficiency. N Engl J Med. 1973;288:813–815.CrossRefPubMedGoogle Scholar
  10. 10.
    Klapdor S, Richter E, Klapdor R. Vitamin D status and per-oral vitamin D supplementation in patients suffering from chronic pancreatitis and pancreatic cancer disease. Anticancer Res. 2012;32:1991–1998.PubMedGoogle Scholar
  11. 11.
    Haas S, Krins S, Knauerhase A, Löhr M. Altered bone metabolism and bone density in patients with chronic pancreatitis and pancreatic exocrine insufficiency. JOP. 2015;16:58–62.PubMedGoogle Scholar
  12. 12.
    Holick MF. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr. 2004;79:362–371.PubMedGoogle Scholar
  13. 13.
    Gubergrits N, Malecka-Panas E, Lehman GA, et al. A 6-month, open-label clinical trial of pancrelipase delayed-release capsules (Creon) in patients with exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery. Aliment Pharmacol Ther. 2011;33:1152–1161.CrossRefPubMedGoogle Scholar
  14. 14.
    Wooldridge JL, Heubi JE, Amaro-Galvez R, et al. EUR-1008 pancreatic enzyme replacement is safe and effective in patients with cystic fibrosis and pancreatic insufficiency. J Cyst Fibros. 2009;8:405–417.CrossRefPubMedGoogle Scholar
  15. 15.
    Munck A, Duhamel JF, Lamireau T, et al. Pancreatic enzyme replacement therapy for young cystic fibrosis patients. J Cyst Fibros. 2009;8:14–18.CrossRefPubMedGoogle Scholar
  16. 16.
    Seiler CM, Izbicki J, Varga-Szabó L, et al. Randomised clinical trial: a 1-week, double-blind, placebo-controlled study of pancreatin 25 000 Ph. Eur. minimicrospheres (Creon 25000 MMS) for pancreatic exocrine insufficiency after pancreatic surgery, with a 1-year open-label extension. Aliment Pharmacol Ther. 2013;37:691–702.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Lévy P, Barthet M, Mollard BR, Amouretti M, Marion-Audibert AM, Dyard F. Estimation of the prevalence and incidence of chronic pancreatitis and its complications. Gastroenterol Clin Biol. 2006;30:838–844.CrossRefPubMedGoogle Scholar
  18. 18.
    Van de Vijver E, Desager K, Mulberg AE, et al. Treatment of infants and toddlers with cystic fibrosis-related pancreatic insufficiency and fat malabsorption with pancrelipase MT. J Pediatr Gastroenterol Nutr. 2011;53:61–64.CrossRefPubMedGoogle Scholar
  19. 19.
    Lieb JG, Draganov PV. Pancreatic function testing: here to stay for the 21st century. World J Gastroenterol. 2008;14:3149–3158.CrossRefPubMedGoogle Scholar
  20. 20.
    Domínguez-Muñoz JE, Nieto L, Vilariño M, Lourido MV, Iglesias-García J. Development and diagnostic accuracy of a breath test for pancreatic exocrine insufficiency in chronic pancreatitis. Pancreas. 2016;45:241–247.CrossRefPubMedGoogle Scholar
  21. 21.
    Chowdhury RS, Forsmark CE. Review article: pancreatic function testing. Aliment Pharmacol Ther. 2003;17:733–750.CrossRefPubMedGoogle Scholar
  22. 22.
    Domínguez-Muñoz JE. Pancreatic exocrine insufficiency: diagnosis and treatment. J Gastroenterol Hepatol. 2011;26:12–16.CrossRefPubMedGoogle Scholar
  23. 23.
    Löser C, Möllgaard A, Fölsch UR. Faecal elastase 1: a novel, highly sensitive, and specific tubeless pancreatic function test. Gut. 1996;39:580–586.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Bilgin M, Bilgin S, Balci NC, et al. Magnetic resonance imaging and magnetic resonance cholangiopancreatography findings compared with fecal elastase 1 measurement for the diagnosis of chronic pancreatitis. Pancreas. 2008;36:e33–e39.CrossRefPubMedGoogle Scholar
  25. 25.
    Walkowiak J, Herzig KH, Strzykala K, Przyslawski J, Krawczynski M. Fecal elastase-1 is superior to fecal chymotrypsin in the assessment of pancreatic involvement in cystic fibrosis. Pediatrics. 2002;110:e7.CrossRefPubMedGoogle Scholar
  26. 26.
    Hardt PD, Marzeion AM, Schnell-Kretschmer H, et al. Fecal elastase 1 measurement compared with endoscopic retrograde cholangiopancreatography for the diagnosis of chronic pancreatitis. Pancreas. 2002;25:e6–e9.CrossRefPubMedGoogle Scholar
  27. 27.
    Domínguez-Muñoz JE, Hieronymus C, Sauerbruch T, Malfertheiner P. Fecal elastase test: evaluation of a new noninvasive pancreatic function test. Am J Gastroenterol. 1995;90:1834–1837.PubMedGoogle Scholar
  28. 28.
    Schneider A, Funk B, Caspary W, Stein J. Monoclonal versus polyclonal ELISA for assessment of fecal elastase concentration: pitfalls of a new assay. Clin Chem. 2005;51:1052–1054.CrossRefPubMedGoogle Scholar
  29. 29.
    Borowitz D, Lin R, Baker SS. Comparison of monoclonal and polyclonal ELISAs for fecal elastase in patients with cystic fibrosis and pancreatic insufficiency. J Pediatr Gastroenterol Nutr. 2007;44:219–223.CrossRefPubMedGoogle Scholar
  30. 30.
    Hardt PD, Hauenschild A, Nalop J, et al. The commercially available ELISA for pancreatic elastase 1 based on polyclonal antibodies does measure an as yet unknown antigen different from purified elastase 1. Binding studies and clinical use in patients with exocrine pancreatic insufficiency. Z Gastroenterol. 2003;41:903–906.CrossRefPubMedGoogle Scholar
  31. 31.
    Miendje Y, Maisin D, Sipewa MJ, et al. Polyclonal versus monoclonal ELISA for the determination of fecal elastase 1: diagnostic value in cystic fibrosis and chronic pancreatic insufficiency. Clin Lab. 2004;50:419–424.PubMedGoogle Scholar
  32. 32.
    Walkowiak J, Glapa A, Nowak JK, et al. Pancreatic Elastase-1 Quick Test for rapid assessment of pancreatic status in cystic fibrosis patients. J Cyst Fibros. 2016;15:664–668.CrossRefPubMedGoogle Scholar
  33. 33.
    Rose SD, MacDonald RJ. Evolutionary silencing of the human elastase I gene (ELA1). Hum Mol Genet. 1997;6:897–903.CrossRefPubMedGoogle Scholar
  34. 34.
    Szepessy E, Sahin-Toth M. Inactivity of recombinant ELA2B provides a new example of evolutionary elastase silencing in humans. Pancreatology. 2006;6:117–122.CrossRefPubMedGoogle Scholar
  35. 35.
    Weiss FU, Budde C, Lerch MM. Specificity of a Polyclonal Fecal Elastase ELISA for CELA3. PLoS ONE. 2016;11:e0159363.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Leeds JS, Hopper AD, Sidhu R, et al. Some patients with irritable bowel syndrome may have exocrine pancreatic insufficiency. Clin Gastroenterol Hepatol. 2010;8:433–438.CrossRefPubMedGoogle Scholar
  37. 37.
    Lévy P, Domínguez-Muñoz E, Imrie C, Löhr M, Maisonneuve P. Epidemiology of chronic pancreatitis: burden of the disease and consequences. United Eur Gastroenterol J. 2014;2:345–354.CrossRefGoogle Scholar
  38. 38.
    Ewald N, Kaufmann C, Raspe A, Kloer HU, Bretzel RG, Hardt PD. Prevalence of diabetes mellitus secondary to pancreatic diseases (type 3c). Diabetes Metab Res Rev. 2012;28:338–342.CrossRefPubMedGoogle Scholar
  39. 39.
    Yin Q, Zou X, Zai X, et al. Pancreatic ductal adenocarcinoma and chronic mass-forming pancreatitis: differentiation with dual-energy MDCT in spectral imaging mode. Eur J Radiol. 2015;84:2470–2476.CrossRefPubMedGoogle Scholar
  40. 40.
    Ketwaroo G, Brown A, Young B, et al. Defining the accuracy of secretin pancreatic function testing in patients with suspected early chronic pancreatitis. Am J Gastroenterol. 2013;108:1360–1366.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Stevens T, Conwell DL, Zuccaro G Jr, et al. A prospective crossover study comparing secretin-stimulated endoscopic and Dreiling tube pancreatic function testing in patients evaluated for chronic pancreatitis. Gastrointest Endosc. 2008;67:458–466.CrossRefPubMedGoogle Scholar
  42. 42.
    Lüth S, Teyssen S, Forssmann K, Kölbel C, Krummenauer F, Singer MV. Fecal elastase-1 determination: ‘gold standard’ of indirect pancreatic function tests? Scand J Gastroenterol. 2001;36:1092–1099.CrossRefPubMedGoogle Scholar
  43. 43.
    Soldan W, Henker J, Sprossig C. Sensitivity and specificity of quantitative determination of pancreatic elastase 1 in feces of children. J Pediatr Gastroenterol Nutr. 1997;24:53–55.CrossRefPubMedGoogle Scholar
  44. 44.
    Lankisch PG, Schmidt I, König H, et al. Faecal elastase 1: not helpful in diagnosing chronic pancreatitis associated with mild to moderate exocrine pancreatic insufficiency. Gut. 1998;42:551–554.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Stein J, Jung M, Sziegoleit A, Zeuzem S, Caspary WF, Lembcke B. Immunoreactive elastase I: clinical evaluation of a new noninvasive test of pancreatic function. Clin Chem. 1996;42:222–226.PubMedGoogle Scholar
  46. 46.
    Walkowiak J, Cichy WK, Herzig KH. Comparison of fecal elastase-1 determination with the secretin-cholecystokinin test in patients with cystic fibrosis. Scand J Gastroenterol. 1999;34:202–207.CrossRefPubMedGoogle Scholar
  47. 47.
    Leodolter A, Kahl S, Domínguez-Muñoz JE, Gerards C, Glasbrenner B, Malfertheiner P. Comparison of two tubeless function tests in the assessment of mild-to-moderate exocrine pancreatic insufficiency. Eur J Gastroenterol Hepatol. 2000;12:1335–1338.CrossRefPubMedGoogle Scholar
  48. 48.
    Siegmund E, Löhr JM, Schuff-Werner P. The diagnostic validity of non-invasive pancreatic function tests—a meta-analysis. Z Gastroenterol. 2004;42:1117–1128.CrossRefPubMedGoogle Scholar
  49. 49.
    Benini L, Amodio A, Campagnola P, et al. Fecal elastase-1 is useful in the detection of steatorrhea in patients with pancreatic diseases but not after pancreatic resection. Pancreatology. 2013;13:38–42.CrossRefPubMedGoogle Scholar
  50. 50.
    Domínguez-Muñoz JE, Lucendo A, Carballo LF, Iglesias-Garcia J, Tenías JM. A Spanish multicenter study to estimate the prevalence and incidence of chronic pancreatitis and its complications. Rev Esp Enferm Dig. 2014;106:239–245.PubMedGoogle Scholar
  51. 51.
    Borowitz D, Baker SS, Duffy L, et al. Use of fecal elastase-1 to classify pancreatic status in patients with cystic fibrosis. J Pediatr. 2004;145:322–326.CrossRefPubMedGoogle Scholar
  52. 52.
    Tseng DS, Molenaar IQ, Besselink MG, van Eijck CH, Borel Rinkes IH, van Santvoort HC. Pancreatic exocrine insufficiency in patients with pancreatic or periampullary cancer: a systematic review. Pancreas. 2016;45:325–330.CrossRefPubMedGoogle Scholar
  53. 53.
    Das SL, Kennedy JI, Murphy R, Phillips AR, Windsor JA, Petrov MS. Relationship between the exocrine and endocrine pancreas after acute pancreatitis. World J Gastroenterol. 2014;20:17196–17205.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Kahl S, Schütte K, Glasbrenner B, et al. The effect of oral pancreatic enzyme supplementation on the course and outcome of acute pancreatitis: a randomized, double-blind parallel-group study. JOP. 2014;15:165–174.PubMedGoogle Scholar
  55. 55.
    Ho TW, Wu JM, Kuo TC, et al. Change of both endocrine and exocrine insufficiencies after acute pancreatitis in non-diabetic patients: a nationwide population-based study. Medicine (Baltimore). 2015;94:e1123.CrossRefGoogle Scholar
  56. 56.
    Shimosegawa T, Chari ST, Frulloni L, et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas. 2011;40:352–358.CrossRefPubMedGoogle Scholar
  57. 57.
    Buijs J, Cahen DL, van Heerde MJ, et al. The long-term impact of autoimmune pancreatitis on pancreatic function, quality of life, and life expectancy. Pancreas. 2015;44:1065–1071.CrossRefPubMedGoogle Scholar
  58. 58.
    Hoffmeister A, Mayerle J, Beglinger C, et al. English language version of the S3-consensus guidelines on chronic pancreatitis: definition, aetiology, diagnostic examinations, medical, endoscopic and surgical management of chronic pancreatitis. Z Gastroenterol. 2015;53:1447–1495.CrossRefPubMedGoogle Scholar
  59. 59.
    Löhr JM, Oliver MR, Frulloni L. Synopsis of recent guidelines on pancreatic exocrine insufficiency. United Eur Gastroenterol J. 2013;1:79–83.CrossRefGoogle Scholar
  60. 60.
    Cohen JR, Schall JI, Ittenbach RF, Zemel BS, Stallings VA. Fecal elastase: pancreatic status verification and influence on nutritional status in children with cystic fibrosis. J Pediatr Gastroenterol Nutr. 2005;40:438–444.CrossRefPubMedGoogle Scholar
  61. 61.
    Weintraub A, Blau H, Mussaffi H, et al. Exocrine pancreatic function testing in patients with cystic fibrosis and pancreatic sufficiency: a correlation study. J Pediatr Gastroenterol Nutr. 2009;48:306–310.CrossRefPubMedGoogle Scholar
  62. 62.
    Symersky T, van der Zon A, Biemond I, Masclee AA. Faecal elastase-I: helpful in analysing steatorrhoea? Neth J Med. 2004;62:286–289.PubMedGoogle Scholar
  63. 63.
    Halloran CM, Cox TF, Chauhan S, et al. Partial pancreatic resection for pancreatic malignancy is associated with sustained pancreatic exocrine failure and reduced quality of life: a prospective study. Pancreatology. 2011;11:535–545.CrossRefPubMedGoogle Scholar
  64. 64.
    Nakamura H, Morifuji M, Murakami Y, et al. Usefulness of a 13C-labeled mixed triglyceride breath test for assessing pancreatic exocrine function after pancreatic surgery. Surgery. 2009;145:168–175.CrossRefPubMedGoogle Scholar
  65. 65.
    Hardt PD, Krauss A, Bretz L, et al. Pancreatic exocrine function in patients with type 1 and type 2 diabetes mellitus. Acta Diabetol. 2000;37:105–110.CrossRefPubMedGoogle Scholar
  66. 66.
    Hardt PD, Hauenschild A, Nalop J, et al. High prevalence of exocrine pancreatic insufficiency in diabetes mellitus. A multicenter study screening fecal elastase 1 concentrations in 1,021 diabetic patients. Pancreatology. 2003;3:395–402.CrossRefPubMedGoogle Scholar
  67. 67.
    Chey WY, Shay H, Shuman CR. External pancreatic secretion in diabetes mellitus. Ann Intern Med. 1963;59:812–821.CrossRefPubMedGoogle Scholar
  68. 68.
    Ewald N, Raspe A, Kaufmann C, Bretzel RG, Kloer HU, Hardt PD. Determinants of exocrine pancreatic function as measured by fecal elastase-1 concentrations (FEC) in patients with diabetes mellitus. Eur J Med Res. 2009;14:118–122.PubMedPubMedCentralGoogle Scholar
  69. 69.
    Hardt PD, Brendel MD, Kloer HU, Bretzel RG. Is pancreatic diabetes (type 3c diabetes) underdiagnosed and misdiagnosed? Diabetes Care. 2008;31:S165–S169.CrossRefPubMedGoogle Scholar
  70. 70.
    Oliveira NM, Ferreira FA, Yonamine RY, Chehter EZ. Antiretroviral drugs and acute pancreatitis in HIV/AIDS patients: is there any association? A literature review. Einstein (Sao Paulo). 2014;12:112–119.CrossRefGoogle Scholar
  71. 71.
    Trivedi CD, Pitchumoni CS. Drug-induced pancreatitis: an update. J Clin Gastroenterol. 2005;39:709–716.CrossRefPubMedGoogle Scholar
  72. 72.
    Deprez PH, Sempoux C, De Saeger C, et al. Expression of cholecystokinin in the duodenum of patients with coeliac disease: respective role of atrophy and lymphocytic infiltration. Clin Sci (Lond). 2002;103:171–177.CrossRefGoogle Scholar
  73. 73.
    Turck D, Braegger CP, Colombo C, et al. ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis. Clin Nutr. 2016;35:557–577.CrossRefPubMedGoogle Scholar
  74. 74.
    Lindkvist B, Phillips ME, Domínguez-Muñoz JE. Clinical, anthropometric and laboratory nutritional markers of pancreatic exocrine insufficiency: prevalence and diagnostic use. Pancreatology. 2015;15:589–597.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • J. Enrique Domínguez-Muñoz
    • 1
  • Philip D. Hardt
    • 2
  • Markus M. Lerch
    • 3
  • Matthias J. Löhr
    • 4
  1. 1.Department of Gastroenterology and HepatologyUniversity Hospital of Santiago de CompostelaSantiago de CompostelaSpain
  2. 2.Medical Department VUniversity HospitalGiessenGermany
  3. 3.Department of Medicine AUniversity Medicine GreifswaldGreifswaldGermany
  4. 4.Department of Digestive DiseasesKarolinska Institutet and Karolinska University HospitalStockholmSweden

Personalised recommendations